PLAUR and urinary bladder cancer: For uPAR targeted-toxin therapy, the receptor binding region of uPA (ATF, residues 1–135) was fused with saporin and the chimeric fusion protein displayed a specific toxic effect in uPAR-expressing bladder cancer xenografted cells, suggesting promising cytotoxic treatements (Fabbrini et al., 1997; Zuppone et al., 2020).